Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keaven M Anderson

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Statistics in Medicine|July 2, 2024
Exploratory subgroup identification in the heterogeneous Cox model: A relatively simple procedureLarry F León, Thomas Jemielita, Zifang Guo, et al.
Statistics in Medicine|August 22, 2025
Prior Effective Sample Size When Borrowing on the Treatment Effect ScaleHongtao Zhang, Keaven M Anderson, Zachary Zimmer, et al.
Biometrics|February 16, 2020
On the empirical choice of the time window for restricted mean survival timeLu Tian, Hua Jin, Hajime Uno, et al.
JAMA Oncology|July 21, 2022
Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysisPralay Mukhopadhyay, Jiabu Ye, Keaven M Anderson, et al.
Journal of the National Cancer Institute|September 13, 2007
Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention TrialYael C Cohen, Kenneth S Liu, Norman L Heyden, et al.
The American Journal of Cardiology|September 17, 2002
Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profileDean J Kereiakes, A Michael Lincoff, Keaven M Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2018
Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic ClearanceDavid C Turner, Anna G Kondic, Keaven M Anderson, et al.
Statistics in Biopharmaceutical Research|June 30, 2021
Rejoinder to Letter to the Editor "The Hazards of Period Specific and Weighted Hazard Ratios"Ray S Lin, Ji Lin, Satrajit Roychoudhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2018
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Statistics in Medicine|July 2, 2024
Exploratory subgroup identification in the heterogeneous Cox model: A relatively simple procedureLarry F León, Thomas Jemielita, Zifang Guo, et al.
Statistics in Medicine|August 22, 2025
Prior Effective Sample Size When Borrowing on the Treatment Effect ScaleHongtao Zhang, Keaven M Anderson, Zachary Zimmer, et al.
Biometrics|February 16, 2020
On the empirical choice of the time window for restricted mean survival timeLu Tian, Hua Jin, Hajime Uno, et al.
JAMA Oncology|July 21, 2022
Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysisPralay Mukhopadhyay, Jiabu Ye, Keaven M Anderson, et al.
Journal of the National Cancer Institute|September 13, 2007
Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention TrialYael C Cohen, Kenneth S Liu, Norman L Heyden, et al.
The American Journal of Cardiology|September 17, 2002
Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profileDean J Kereiakes, A Michael Lincoff, Keaven M Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2018
Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic ClearanceDavid C Turner, Anna G Kondic, Keaven M Anderson, et al.
Statistics in Biopharmaceutical Research|June 30, 2021
Rejoinder to Letter to the Editor "The Hazards of Period Specific and Weighted Hazard Ratios"Ray S Lin, Ji Lin, Satrajit Roychoudhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2018
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Pageof 2